NCT06439225 2026-04-16
OPTION-DDR
Canadian Cancer Trials Group
Phase 3 Recruiting
Clinical Trials
30 trialsNCT07213674 2026-04-16
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
NCT06136650 2026-04-15
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06122584 2026-04-14
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
ABX advanced biochemical compounds GmbH
Phase 3 Recruiting
NCT06235697 2026-04-14
ASCENDE-SBRT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06592924 2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT01946204 2026-04-13
SPARTAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02257736 2026-04-13
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02489318 2026-04-13
TITAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02531516 2026-04-13
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT03767244 2026-04-13
PROTEUS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04557059 2026-04-13
PRIMORDIUM
Janssen Pharmaceutica N.V., Belgium
Phase 3 Active not recruiting
NCT06925737 2026-04-13
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06056830 2026-04-09
CLARIFY
Clarity Pharmaceuticals Ltd
Phase 3 Recruiting
NCT06970847 2026-04-09
AMPLIFY
Clarity Pharmaceuticals Ltd
Phase 3 Recruiting
NCT06235151 2026-04-08
Solar-Stage
Curium US LLC
Phase 3 Recruiting
NCT04821622 2026-04-07
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Pfizer
Phase 3 Active not recruiting
NCT06931340 2026-04-07
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT04423211 2026-04-03
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04513717 2026-04-03
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT05946213 2026-04-03
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
Phase 3 Recruiting
NCT06120491 2026-04-03
EvoPAR-PR01
AstraZeneca
Phase 3 Recruiting
NCT04493853 2026-04-01
CAPItello-281
AstraZeneca
Phase 3 Active not recruiting
NCT02064673 2026-03-30
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
University of Texas Southwestern Medical Center
Phase 3 Recruiting
NCT07028853 2026-03-30
MEVPRO-3
Pfizer
Phase 3 Recruiting
NCT07500701 2026-03-30
Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer
Samsung Medical Center
Phase 3 Recruiting
NCT05678322 2026-03-25
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
NYU Langone Health
Phase 3 Active not recruiting
NCT04484818 2026-03-23
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT04689828 2026-03-23
PSMAfore
Novartis
Phase 3 Active not recruiting
NCT03594760 2026-03-19
PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 3 Recruiting